Rapamycin (Sirolimus) and Finasteride Interaction: What Women Need to Know

What Is the Interaction Between Rapamycin and Finasteride?

No published pharmacokinetic trial has directly studied the sirolimus-finasteride combination in humans. The interaction concern is two-fold: a theoretical pharmacodynamic overlap through androgen-pathway modulation, and the shared obligation to avoid both drugs during pregnancy and conception. For most women taking these drugs off-label, the clinical question is not "will sirolimus levels spike?" but rather "do these two drugs compound reproductive risk, and is this combination appropriate at my life stage?"

How Rapamycin Is Metabolized

Sirolimus is almost entirely dependent on CYP3A4 and P-glycoprotein (P-gp) for its absorption and clearance. This means its blood levels shift dramatically with anything that inhibits or induces CYP3A4, azole antifungals, certain macrolide antibiotics, grapefruit juice, and St. John's Wort are the headline offenders. The FDA-approved sirolimus (Rapamune) prescribing information lists CYP3A4 inhibitors and inducers as the primary interaction category and mandates whole-blood trough monitoring when any interacting agent is added or removed.

How Finasteride Is Metabolized

Finasteride is metabolized primarily by CYP3A4, producing inactive metabolites excreted in urine and feces. Because both sirolimus and finasteride use CYP3A4, a theoretical competitive substrate interaction exists. In practice, finasteride's clinical exposure (1 mg for hair loss, 5 mg for BPH/androgenic conditions) is low enough that it is not considered a clinically meaningful CYP3A4 inhibitor. The FDA finasteride label does not list sirolimus as a recognized interaction. No peer-reviewed pharmacokinetic study has quantified whether finasteride alters sirolimus trough levels in any meaningful way.

The Pharmacodynamic Overlap: Androgen Pathway

Finasteride blocks 5-alpha reductase (5-AR), the enzyme that converts testosterone to the more potent dihydrotestosterone (DHT). Rapamycin inhibits mTORC1, a serine/threonine kinase that sits at a convergence point of nutrient sensing, protein synthesis, and, relevant here, androgen-receptor signaling. Preclinical data suggest mTOR inhibition can suppress androgen-receptor transcription in certain tissue contexts, meaning sirolimus and finasteride may act on overlapping downstream androgen-sensitive pathways through entirely different molecular entry points. Whether this additive suppression of androgen signaling is clinically meaningful for women has not been studied in any published human trial.

A working clinical framework: classify the rapamycin-finasteride interaction as pharmacodynamic-theoretical, severity unclear, with shared reproductive-safety concern. The drug-drug interaction (DDI) databases (Lexicomp, Micromedex, Clinical Pharmacology) do not assign a severity rating to this pair, which reflects the absence of data rather than a guarantee of safety.

Why Women Are Taking These Drugs (Life-Stage Context)

Finasteride in Women

Finasteride 1 mg is FDA-approved only in men for androgenetic alopecia. Its use in women is entirely off-label. The groups most likely to be prescribed it are:

Reproductive-age women with PCOS. Polycystic ovary syndrome affects 8-13% of reproductive-age women globally and is the most common cause of female hyperandrogenism. Elevated androgens drive hirsutism and female pattern hair loss (FPHL) in PCOS. A 2020 meta-analysis in Fertility and Sterility found finasteride reduced Ferriman-Gallwey hirsutism scores in women with PCOS, though spironolactone showed similar efficacy. Finasteride in this group requires confirmed, reliable contraception because of teratogenicity.

Postmenopausal women with FPHL. After menopause, estrogen decline unmasks androgenic hair loss in genetically predisposed women. A randomized controlled trial published in the British Journal of Dermatology (Iorizzo et al., 2006) found finasteride 1 mg daily did not outperform placebo in postmenopausal women with FPHL, while a later trial by Camacho-Martinez (2010) using 2.5 mg showed modest benefit. Evidence in postmenopausal women remains mixed.

Perimenopausal women. The transition into menopause is when FPHL often accelerates. Finasteride may be considered here, but the evidence base is thin, and irregular cycles mean pregnancy risk cannot be assumed to be zero until menopause is confirmed (12 consecutive months of amenorrhea).

Rapamycin (Sirolimus) in Women

Sirolimus is FDA-approved for renal transplant rejection prophylaxis, certain renal angiomyolipomas, and lymphangioleiomyomatosis (LAM), a progressive lung disease that almost exclusively affects women of reproductive age. Off-label, it is gaining traction in longevity medicine at low intermittent doses (typically 1-6 mg once weekly), where early data suggest immunomodulatory and potential anti-aging effects.

Women taking rapamycin are therefore a heterogeneous group: solid-organ transplant recipients, women with LAM, and an emerging cohort seeking longevity optimization.

Pregnancy, Lactation, and Contraception: A Required Section

This section is mandatory reading before combining these drugs.

Finasteride and Pregnancy

Finasteride is FDA Pregnancy Category X. It is contraindicated in pregnancy. Finasteride inhibits DHT synthesis during a critical developmental window; male fetuses exposed in utero can develop ambiguous genitalia, a condition called hypospadias or abnormal genital development. The label warns that women who are pregnant or may become pregnant should not handle crushed or broken finasteride tablets because of dermal absorption risk. This is not a theoretical concern. Women of reproductive potential taking finasteride must use highly effective contraception throughout treatment and for at least one month after stopping.

Sirolimus and Pregnancy

Sirolimus is FDA Pregnancy Category C. Animal studies showed embryo-fetal toxicity at doses producing blood levels below the human therapeutic range. Human data are limited almost entirely to transplant recipients, where a 2021 analysis in the American Journal of Transplantation found mTOR inhibitor exposure in early pregnancy was associated with increased risk of pregnancy loss and preterm birth. Standard transplant practice is to switch from mTOR inhibitors to calcineurin inhibitors before a planned pregnancy. The ACOG Committee Opinion on immunosuppression in pregnancy advises individualized counseling for transplant recipients planning conception.

Women on sirolimus for LAM should discuss pregnancy intent explicitly with their pulmonologist and maternal-fetal medicine specialist; the LAM Foundation guidelines recommend stopping sirolimus at least one month before attempted conception.

Lactation

Sirolimus transfers into breast milk. Case reports show detectable sirolimus levels in human milk, and the drug's narrow therapeutic window in transplant recipients makes neonatal exposure a serious concern. Breastfeeding is generally discouraged in women on therapeutic-dose sirolimus.

Finasteride has not been detected in human milk in any published case report, but the absence of data is not clearance. Given the Category X teratogenicity profile and the drug's mechanism of action on androgen pathways relevant to neonatal development, most clinicians advise against use while breastfeeding.

Contraception Requirement

Any woman taking finasteride who retains a uterus and has not reached confirmed menopause must use highly effective contraception. The prescribing information recommends at least one month post-discontinuation. Sirolimus itself may interact with oral contraceptives: one pharmacokinetic study found sirolimus co-administration modestly increased ethinyl estradiol AUC, a finding that does not reduce contraceptive efficacy but is worth noting for side-effect monitoring. IUDs (hormonal or copper) are a preferred contraceptive choice in women on both agents because they avoid this PK interaction entirely.

CYP3A4: Where Most Real Rapamycin Interactions Live

For women combining sirolimus with other medications, the CYP3A4 pathway is where the practical action is, not the finasteride pair specifically.

Strong CYP3A4 Inhibitors (Raise Sirolimus Levels)

Common in women's-health prescribing:

• Fluconazole (common for vulvovaginal candidiasis, especially in women on immunosuppression)
• Ketoconazole
• Clarithromycin
• Verapamil
• Grapefruit or Seville orange juice

A single 200-mg dose of fluconazole can increase sirolimus AUC by approximately 7-fold. Women on transplant-dose sirolimus who develop a yeast infection must notify their transplant team before accepting a fluconazole prescription.

Strong CYP3A4 Inducers (Lower Sirolimus Levels)

• Rifampicin (used in some gynecologic infections)
• Phenytoin, carbamazepine, phenobarbital
• St. John's Wort (a common OTC supplement marketed for mood in perimenopausal women)

St. John's Wort co-administration reduced sirolimus AUC by approximately 43% in one pharmacokinetic study, a clinically significant drop that could precipitate transplant rejection. This is a supplement women frequently use without disclosing to prescribers.

Where Finasteride Sits in This Picture

Finasteride does not meaningfully inhibit or induce CYP3A4 at therapeutic doses. The FDA finasteride label states it showed no effect on the pharmacokinetics of antipyrine, digoxin, propranolol, theophylline, or warfarin in dedicated interaction studies. Sirolimus was not tested in those studies, but based on finasteride's CYP inhibition profile (essentially none at 1-5 mg), a clinically meaningful change in sirolimus trough levels is unlikely.

Androgen-Pathway Pharmacodynamics: Does Combining These Drugs Compound Anything?

This is the more nuanced question, and the honest answer is: we don't fully know.

mTOR and Androgen-Receptor Cross-Talk

Preclinical research has established that the mTOR pathway and androgen signaling are not independent. mTORC1 activity can upregulate androgen-receptor protein synthesis, and rapamycin's inhibition of mTORC1 may attenuate androgen-receptor-driven gene expression in certain cell types, notably prostate cancer cells in male oncology models. Whether this same cross-talk is clinically relevant in the skin, ovarian, or adrenal tissue of women is not established by published human data.

PCOS: A Specific Concern

In women with PCOS, where both drugs might theoretically be co-prescribed (sirolimus for insulin-sensitization off-label, finasteride for hyperandrogenism), the combined androgen suppression could theoretically deepen the hormonal changes beyond what either drug achieves alone. No published human trial has tested this combination in PCOS. Prescribers should monitor free androgen index, SHBG, and DHEAS at baseline and at three to six months if both drugs are in use.

Hair Loss: Could They Complement Each Other?

Some longevity-medicine practitioners are combining low-dose rapamycin with topical or oral finasteride for hair loss, based on the hypothesis that mTOR inhibition and DHT blockade act on different phases of the hair cycle. This is speculative. No RCT exists. Women considering this combination for FPHL should understand they are in uncharted clinical territory.

Who This Is and Is Not Right For

Women for Whom This Combination Might Be Considered

• Postmenopausal women (confirmed 12+ months of amenorrhea) with FPHL who are already on low-dose rapamycin for longevity or LAM management and have a dermatologist recommending finasteride. Teratogenicity is not a concern post-menopause, though reproductive-safety monitoring still applies for other risks.
• Transplant recipients past reproductive age on sirolimus who develop androgenetic alopecia.

Women for Whom This Combination Raises Red Flags

• Women of reproductive potential taking finasteride without confirmed, highly effective contraception. Full stop.
• Women with LAM on sirolimus who are within childbearing years and considering finasteride for hair loss. The reproductive risk of sirolimus already requires careful planning; adding a Category X agent compounds that obligation.
• Women with active liver disease. Both sirolimus and finasteride are hepatically metabolized. Sirolimus half-life is prolonged significantly in hepatic impairment, raising drug-accumulation risk.
• Women on multiple CYP3A4-active medications (azole antifungals, HIV antiretrovirals, antiepileptics). The CYP3A4 burden from those agents is already the primary interaction risk for sirolimus; adding finasteride is a lower-priority concern, but a comprehensive medication review is essential.

Monitoring Protocol When These Drugs Are Co-Prescribed

If a clinician decides this combination is appropriate, the following monitoring applies:

| Parameter | Baseline | Frequency on Therapy | |---|---|---| | Sirolimus whole-blood trough | Yes | Every 1-2 weeks until stable, then every 3 months | | Liver function tests (AST, ALT, bilirubin) | Yes | Every 3 months | | Lipid panel (TG, LDL, HDL) | Yes | Every 6 months (sirolimus raises triglycerides) | | CBC with differential | Yes | Every 3 months (sirolimus is myelosuppressive) | | Free androgen index, SHBG | Yes (if PCOS or hyperandrogenism) | Every 6 months | | Pregnancy test (if reproductive-age) | Before starting | Monthly if any contraceptive uncertainty |

Sirolimus therapeutic trough targets differ by indication: transplant recipients typically target 4-12 ng/mL depending on protocol, while off-label longevity dosing (1-6 mg once weekly) is not associated with a validated trough target in published literature.

Patient Counseling Points for Women

These are the specific things to know before leaving a prescriber's office with both prescriptions:

1. Finasteride is teratogenic. If there is any possibility of pregnancy, you need a contraceptive plan confirmed before the first dose.
2. Tell every provider about both drugs. Sirolimus blood levels shift with common medications, including OTC supplements like St. John's Wort and foods like grapefruit.
3. Report new symptoms promptly: mouth sores, unusual infections, unusual fatigue, or changes in your menstrual cycle. Sirolimus is immunosuppressive even at low doses and can cause irregular cycles.
4. Scalp shedding may get worse before it gets better with either drug. Neither rapamycin nor finasteride shows meaningful hair regrowth until at least six months of consistent use.
5. Lab work is not optional. Skipping sirolimus trough monitoring turns a manageable drug into an unpredictable one.

The Evidence Gap for Women

Women were largely excluded from early sirolimus pharmacokinetic trials. Most published sirolimus DDI studies used male subjects or mixed-sex cohorts where sex-disaggregated data were not reported. Finasteride's off-label use in women has generated a modest but growing evidence base primarily in PCOS and postmenopausal FPHL, but no published trial has examined the sirolimus-finasteride pair. The monitoring recommendations above are extrapolated from each drug's individual label, known metabolic pathways, and general DDI principles, not from direct human data on the combination.

This honest framing is not a reason to avoid either drug when indicated. It is a reason to work with a clinician who understands both, tracks levels, and adjusts the plan based on your labs and your life stage.